Approvals in past 5 years: 7
Value of recent approvals: $17.41 billion
Percent of value from recent approvals: 11.54%
When it comes to recent new drug approvals, none are as lucrative as Pfizer's BioNTech-partnered COVID-19 vaccine Comirnaty, which the partners currently expect to reel in some $33.5 billion in global sales for the year.
That's easily more than enough to eclipse the world's best-selling drug last year, AbbVie's Humira, which generated 2020 sales of about $20 billion. Still, Pfizer's mRNA-based vaccine has yet to score a full FDA nod, and so it isn't included on EvaluatePharma and Evaluate Vantage's recent analysis of 11 Big Pharmas' pipeline wins from recent years.
The analysts specifically looked at the new molecules approved over the past 5 years, and in Pfizer's case, the list features drugs such as the company's rare disease launch Vyndaqel, plus its cancer meds Daurismo, Lorbrena and Talzenna.
All told, Pfizer's seven recent new drug approvals account for a present value of $17.4 billion, the analysts said. The net present value for all the company's products sits at $150.87 billion, while Pfizer's new offerings comprise 12% of the total.
Pfizer ranks in the middle of its pharma peers on number of approvals, but the overall value it's seeing from new meds lags some of the top players in this report. For Roche, AbbVie and AstraZeneca, recent launches carry net present values of $99.78 billion, $76.44 billion and $45.5 billion, respectively.
Leading Pfizer's launch roster is Vyndaqel, which debuted in 2019 to treat a rare heart condition and reached blockbuster status during its first full year on the market. The drug, approved in cardiomyopathy caused by transthyretin-mediated amyloidosis (ATTR-CM), drummed up 2020 sales of $1.3 billion.
The medicine boasts Pfizer's highest single-product net present value by far at $10.61 billion, the Evaluate analysts said. For context, acute myeloid leukemia drug Daurismo carries the next-highest net present value at $2.74 billion.
Also on the oncology front, Lorbrena and Talzenna each boast values in the billions of dollars by Evaluate calculations. Lorbrena, approved in November 2018 for certain metastatic non-small cell lung cancer patients, carries the next highest value after Vyndaqel and Daursimo at $2.22 billion. Talzenna, approved to treat HER2-negative locally advanced or metastatic breast cancer with a BRCA mutation in 2018, is worth $1.47 billion, the team says.
Not all of Pfizer's products have been major winners, though. Pfizer's lung cancer drug Vizimpro has a net present value of $261 million, while Eurcrisa, the company's 2018 atopic dermatitis launch, is worth just $88 million, the Evaluate team said. Meanwhile, acute lymphoblastic leukemia drug Besponsa doesn't have any present value, according to the analysts.
Of course, Pfizer's biggest launch is its massively successful COVID-19 vaccine. Developed with German mRNA expert BioNTech, the shot was the first to snag an emergency use authorization in the U.S. late last year. Pfizer and BioNTech have repeatedly had to recalibrate their vaccine revenue forecasts upwards and may have to do so again now that the FDA has authorized booster shots for the immunocompromised. The shot is set to break just about every pharma record in the books.